Overview

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2019-05-08
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab